Case Report: Rare Presentation of Mixed Germ Cell Tumor in an Infant

Sriharsha Talluri1, Michael A. Goedde1, Susan Coventry2, Eran Rosenberg1,3, Katie L. Canalichio1,3, Dennis Peppas1,3 and Jeffrey T. White1,3*

1 Department of Urology, University of Louisville, Louisville, KY, United States, 2 Department of Pediatric Anatomic Pathology, Norton Healthcare, Louisville, KY, United States, 3 Department of Pediatric Urology, Norton Healthcare, Louisville, KY, United States

The estimated incidence of pediatric testis tumor is 0.5–2.0 per 100,000 children, accounting for 1–2% of all pediatric tumors. Mixed germ cell tumors (MGCT) in prepubertal males are exceedingly rare, with only one previous case report found in the literature. We report a case of a MGCT in an infant. For prepubertal males, GCTs typically present with a painless scrotal mass, though trauma, testis torsion and hydrocele are also common presentations. Similar to such tumors in postpubertal males, ultrasonography, computed tomography, and tumor markers are integral to determine the best treatment.

The patient described in this report presented with a painless scrotal mass. Following orchiectomy, the patient was found to have MGCT that was limited to the testis. With prudent management, these patients tend to have favorable prognoses.

Keywords: pediatric urology, germ cell tumor, testicular tumor, pediatric cancer, surgery

INTRODUCTION

Prepubertal testicular tumors are rare. The total incidence of all testicular tumors is modeled with a bi-modal distribution, most prevalent within the first 2 years of life and young adulthood (1). Pediatric testis tumor incidence is reported as 0.5–2.0 per 100,000 children; testis tumors account for 1–2% of all pediatric tumors (2). The most common testicular tumors in adults are seminomas and mixed germ cell tumors (MGCT). The most common testis tumor in children is yolk sac tumor (YST). There is one previous report that discusses a case of MGCT in prepubertal children in depth (3), though one series did mention a few cases (4). Despite the differing incidence in tumor types between adults and children, general management of pediatric testicular tumors follows a similar algorithm (1). We present an extremely rare case of a MGCT in an infant with only one other case in the literature previously reported.

CASE DESCRIPTION

A 7-week-old male presented to the emergency department with a 1-day history of painless scrotal swelling. On examination, a firm, irregular, non-tender right testis was palpated, but he was otherwise healthy. This child had no prenatal history and was born at full term. His scrotal exam at birth was unremarkable. There was no prior family history of cancer or testis masses. There were no known prenatal exposures to carcinogens. Complete blood count and basic metabolic panel were within normal limits. Color Doppler ultrasound (Figure 1A) revealed an enlarged, heterogeneous, macronodular right testicle with cystic areas. Arterial and venous flow were preserved with hyperemia of the abnormal testis. Tumor markers were obtained. Beta-human chorionic gonadotropin (HCG) was <2.4 IU/L (Ref. <2.4 IU/L) and alpha-fetoprotein (AFP) was...
1,400 ng/ml (Ref. <2,433 ng/mL); lactate dehydrogenase (LDH) was 759 U/L (Ref. 180–430 U/L), making it only the tumor marker that was found to be abnormal. The patient underwent a right radical orchiectomy via the inguinal approach (Figure 1B). The spermatic cord was ligated at the level of the internal inguinal ring. Patient had a normal postoperative course without complication. Pathology revealed immature teratoma >80% and yolk sac tumor < 20%. Tumor was limited to the testis with no lymphovascular invasion (Figure 2). CT chest, abdomen, and pelvis was performed; no extratesticular masses or abnormalities were discovered. There was no evidence of metastatic disease. This patient was classified as AJCC stage I and planned for close surveillance. He is pending enrollment in COG protocol AGCT1531 with oncology. He will undergo monthly tumor markers. CT of the abdomen/pelvis and chest X-ray will be performed at 3 and 12-months post-orchiectomy. Testicular ultrasounds will be performed at 6 months and annually thereafter.

## DISCUSSION

Germ cell tumors (GCTs) account for nearly 98% of all testicular tumors in adults (5). Those tumors that are classified as GCTs can be further broken down into the following groups: germ cell neoplasia in situ (GCNIS), seminoma, and non-seminomatous germ cell tumors [spermatocytic, embryonal carcinoma, yolk sac tumor (YST), choriocarcinoma, and teratoma]. Some tumors can possess features of multiple types and are, therefore, designated as mixed GCTs (5).

Though testicular GCTs are most common following puberty, the distribution of GCTs is bimodal with a significant number occurring during the first year of life (6). The most common postpubertal GCT is YST followed by the mixed subtype (7), while the stratification for the prepubertal cohort is quite different. YSTs and teratomas are responsible for 49% and 13% of cases in the prepubertal patients, respectively. This specific study included adolescents into the category of pediatric tumors, with no prepubertal tumors being classified as MGCT or seminomas (1). A study by Ye et al., found that <4% of pediatric patients with testicular GCT had a MGCT (4). Recent publications have suggested that GCTs that arise in postpubertal patients should be stratified separately from prepubertal patients (8). In addition, GCNIS can be found adjacent to the majority of postpubertal GCTs; GCNIS is rarely found in association with GCT in prepubertal patients (9–11).

For prepubertal males, GCTs typically present with a painless scrotal mass, though trauma, testis torsion and hydrocele are also common presentations (12). A thorough physical exam is conducted to rule out other diagnoses such as inguinal hernia, epididymitis, or testicular torsion. Duplex Doppler ultrasonography should be utilized to characterize the lesion, allowing for a non-invasive assessment while also maintaining a sensitivity of nearly 100% in detecting GCTs (13). In addition to ultrasonography, tumor markers can prove beneficial. Elevated AFP levels can diagnose tumors with a yolk sac component; it is elevated in 90% of yolk sac tumors. This must be interpreted with caution: AFP can be naturally elevated during the first 6 months of life, allowing for benign masses to be mistaken for malignant tumors (1). A markedly elevated β-hCG level occurs in the setting of choriocarcinoma, although seminomas and embryonal carcinomas can have a modest increase as well (14). Rises in levels of lactate dehydrogenase (LDH) are not specific to one type of GCT but does indicate a larger tumor burden (15). Following orchiectomy, these tumor marker levels should be repeated monthly to ensure appropriate decreases and to monitor for disease recurrence.

The most common benign prepubertal masses are teratomas and epidermoid cysts. Prepubertal testis tumors are largely benign, thus surveillance with imaging or an excisional biopsy with frozen section analysis are viable options. There are multiple approaches to prepubertal masses, but surveillance or excisional biopsy may be preferred in all prepubertal tumors, except for those in children older than 6 months of age with an elevated alpha-fetoprotein. This preference is due to the high incidence of yolk sac tumors (1). Some urologists will approach a prepubertal testis tumor and normal tumor markers with a testis-sparing surgery and frozen section. If the frozen section reveals a benign histology, the testis can be spared. On the other hand, completion orchiectomy should follow if a malignant subtype is present in the frozen section (14). While teratoma is usually benign in adults, the majority of teratomas may harbor surrounding carcinoma in situ (CIS). This is in contrast to prepubertal children (16). Thus, prepubertal and postpubertal teratomas may require different management algorithms (17). The prognosis for prepubertal teratoma is favorable (18).

Many factors, such as tumor markers and risk factors for metastasis, affect the level of treatment that is needed for patients following resection. For this reason, the Children’s Cancer Group/Pediatric Oncology Group (CCG/POG) has developed a staging system to help stratify tumors for management (Table 1) (19). For stage I YSTs and MGCTs in prepubertal boys, it is recommended that follow-up physical exams, tumor markers levels, and abdominal CT imaging be used to assess for recurrence. CCG/POG reported that this approach yielded a near 100% 5-year survival for Stage I patients (19). For prepubertal stages II–IV YSTs and MGCTs, surgical resection should be followed by a combination of bleomycin, etoposide, and cisplatin (BEP). If residual disease exists or tumor markers remain elevated, salvage chemotherapy and resection of remaining tumor should be considered (20). Though post-resection management for postpubertal YSTs and MGCTs is similar to that of prepubertal cases, there are a few differences. For stage I postpubertal tumors, surveillance is also the first line option (21). Like prepubertal tumors, stage II postpubertal tumors are best managed with BEP (22). However, one group that does have a different treatment for postpubertal patients is Stage IIa disease (with metastasis to lymph nodes that is <2 cm and involves ≤5 lymph nodes) with normal tumor markers. For these patients, the preferred treatment is retroperitoneal lymph node dissection (23).
FIGURE 1 | (A) Color Doppler ultrasonography showed an enlarged, heterogeneous, macronodular right testicle with cystic areas. Both arterial and venous flow were preserved, but hyperemia of the abnormal testis was present. (B) The testis and spermatic cord were accessed via an inguinal incision.

FIGURE 2 | (A) The majority of the tumor comprises immature teratoma with a predominance of primitive neuroepithelium (bottom right) and a smaller primitive mesenchymal component (nodule of immature cartilage on the left). (B) There were rare small foci of yolk sac tumor with primitive glandular structures as well as a hepatoid focus demonstrating cords of immature cells with more abundant eosinophilic cytoplasm and occasional small nucleoli. (C) This focus is strongly AFP-positive.

TABLE 1 | Children’s Cancer Group/Pediatric Oncology Group (CCG/POG) staging system [modified from Schlatter et al. (19)].

| CCG/POG grading of testicular germ cell tumors |
|-----------------------------------------------|
| Stage I                                      |
| - Limited to the testis                      |
| - Removed in its entirety during high inguinal orchiectomy |
| - Has an appropriate decrease in tumor markers following its removal |
| Stage II                                     |
| - Invades to the scrotum and/or high spermatic cord |
| - Has retroperitoneal lymphadenopathy         |
| - May be resected via transcrotalorchietomy   |
| - Does not have an appropriate return of tumor markers to normal levels |
| Stage III                                    |
| - Has advanced retroperitoneal lymph node involvement that is >2 cm wide |
| - Has not spread to viscera or other areas of the body |
| Stage IV                                     |
| - Presence of distant metastasis              |

We present a rare case of a MGCT in an infant. There is one other case report in the literature. The other case was histologically similar and comprised of teratoma and yolk sac tumor in a newborn (3). Despite its rarity, both were classified as Stage I tumors, in which the patients underwent active surveillance. With prudent management both patients should achieve favorable long-term outcomes. Further cases will need to be reported and current cases actively monitored to determine whether changes to therapeutic options are needed for Stage I testis tumors in prepubertal males.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.
AUTHOR CONTRIBUTIONS

All authors have made significant contributions to the manuscript including design, drafting and revising, and approved the final manuscript and its submission to Frontiers.

REFERENCES

1. Ross JH, Kay R. Prepubertal testis tumors. Rev Urol. (2004) 6:11–8.
2. Coppes MJ, Rackley R, Kay R. Primary testicular and paratesticular tumors of childhood. Med Pediatr Oncol. (1994) 22:329–40. doi: 10.1002/mpo.2950220506
3. Singh AP, Tanger R, Mishra D, Ansari M, Gupta AK, Shukla AK. Testicular mixed germ cell tumor in a newborn child: a rare case. J Indian Assoc Pediatr Surg. (2019) 24:144–6. doi: 10.4103/jiaps.JIAPS_87_18
4. Ye YL, Sun ZX, Zheng FF, Bian J, Huang YP, Zhang XQ, et al. Clinical analysis of management of pediatric testicular germ cell tumors. Urology. (2012) 79:892–7. doi: 10.1016/j.urology.2011.07.1422
5. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization classification of tumours. In: Piatigorsky J, ed. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press (2004) 216–78.
6. Poynter JN, Amatruda JE, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer. (2010) 116:4882–91. doi: 10.1002/cncr.25454
7. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study–Pediatric Oncology Group 9049 and Children’s Cancer Group 8882. J Clin Oncol. (2004) 22:2691–700. doi: 10.1200/JCO.2004.08.015
8. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. (2016) 70:93–105. doi: 10.1016/j.eurouro.2016.02.029
9. Manivel JC, Reinberg Y, Niehans GA, Fraley EE. Intratubular germ cell neoplasia in testicular teratomas and epidermoid cysts. Correlation with prognosis and possible biologic significance. Cancer. (1989) 64:715–20. doi: 10.1002/1097-0142(19890801)64:3<715::AID-CNCR28280640325>3.0.CO;2-I
10. Cheng L, Lyu B, Roth LM. Perspectives on testicular germ cell neoplasms. Hum Pathol. (2017) 59:10–25. doi: 10.1016/j.humpath.2016.08.002
11. Hawkins E, Heifetz SA, Giller R, Cushing B. The prepubertal testis (prepubertal and postnatal): its relationship to intratubular germ cell neoplasia: a combined Pediatric Oncology Group and Children’s Cancer Study Group. Hum Pathol. (1997) 28:404–10. doi: 10.1016/S0046-8177(97)0027-7
12. Metcalfe PD, Farivar-Mohseni H, Farhat W, McLawrie G, Khoury A, Bagli DJ. Pediatric testicular tumors: contemporary incidence and efficacy of testicular preserving surgery. J Urol. (2003) 170(6 Pt 1):2412–6. doi: 10.1016/j.juros.2003.09.073
13. Sangüesa C, Veiga D, Lavrador M, Serrano A. Testicular tumours in children: an approach to diagnosis and management with pathologic correlation. Insights Imaging. (2020) 11:74. doi: 10.1186/s13244-020-00867-6
14. Grantham EC, Caldwell BT, Cost NG. Current urologic care for testicular germ cell tumors in pediatric and adolescent patients. Urol Oncol. (2016) 34:65–75. doi: 10.1016/j.urolonc.2015.06.008
15. Carl J, Christensen TR, von der Maase H. Cisplatinum dose dependent response in germ cell cancer evaluated by tumour marker modelling. Acta Oncol. (1992) 31:749–53. doi: 10.3109/02841869209083865
16. Ross JH, Kay R, Elder J. Testis sparing surgery for pediatric epithelial cysts of the testis. J Urol. (1993) 149:353–6. doi: 10.1016/S0022-5347(17)36080-9
17. Renedo DE, Trainer TD. Intratubular germ cell neoplasia (ITGCN) with p53 and PCNA expression and adjacent mature teratoma in an infant testis. An immunohistochemical and morphologic study with a review of the literature. Am J Surg Pathol. (1994) 18:947–52. doi: 10.1097/00000478-199409000-00010
18. Liu P, Li W, Song HC, Jiao LL, Zhang WP, Sun N. Characteristics, treatment decisions and outcomes of prepubertal testicular germ cell tumor: a descriptive analysis from a large Chinese center. J Pediatr Urol. (2018) 14:443.e1–7. doi: 10.1016/j.ipeduro.2018.02.030
19. Schlammer M, Rescorla F, Giller B, Cushing B, Vinocur C, Colombani P, et al. Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children’s Cancer Group/Pediatric Oncology Group. J Pediatr Surg. (2003) 38:319–24. doi: 10.1053/jpsu.2003.30101
20. Rogers PC, Olson TA, Cullen JW, Bilmire DF, Marina N, Rescorla F, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup Study–Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol. (2004) 22:5563–9. doi: 10.1200/JCO.2004.01.006
21. Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. (2013) 31:3490–3. doi: 10.1200/JCO.2012.47.6010
22. Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II nonseminomatous testis tumor. J Urol. (1991) 146:1295–8. doi: 10.1016/S0022-5347(17)38072-2
23. Donohue JP, Thornhill JA, Foster RS, Bihle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol. (1995) 153:85–9. doi: 10.1097/0005392-199501000-00030

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2021.729917/full#supplementary-material

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Talluri, Goede, Coventry, Rosenberg, Canali, Pappas and White. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.